The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta

Stopped Eli Lilly has withdrawn support to the study of teriparatide and placebo pens. The study was not able to continue as a randomized study without the supply of placebo pens.

Conditions

• Osteogenesis Imperfecta

Interventions

• DRUG: Zoledronic acid
• DRUG: Teriparatide
• OTHER: No active treatment

Sponsor

University of Aarhus